论文部分内容阅读
目的 制备13 1I 抗 VEGFMcAb( 13 1I sc 72 69) ,并探讨其作为肿瘤放射免疫显像剂的可能性。方法 采用Iodogen法碘化标记制备13 1I sc 72 69。SephadexG5 0分离纯化标记产物 ,三氯醋酸法测定标记产物的放射化学纯度 ,体外细胞结合分析法鉴定13 1I sc 72 69的免疫结合活性。结果 ①13 1I标记率为 2 7.46% ,标记产物的放射性比活度为 1.0 2MBq/μg ,平均放射性化学纯度为96.2 0 %。平均放射性浓度为 18.3 0MBq/ml。②体外结合分析显示 ,13 1I sc 72 69与人膀胱癌T2 4细胞结合率达 5 9.12 % ,而与人脐静脉血管内皮细胞结合率仅为 7.16% (P <0 .0 0 1)。13 1I sc 72 694℃保存 7d后与T2 4细胞的结合率仍为 5 6.3 1%。结论 本实验制备的13 1I sc 72 69,其放射性化学纯度 >95 % ,有良好的免疫活性和稳定性 ,具备作为放射性显像剂的条件。
Objective To prepare 131I anti-VEGFMcAb (131I sc 72 69) and explore its potential as a radioimmunoimaging agent for tumors. Methods The Iodogen method was used to prepare 13 1I sc 72 69. SephadexG5 0 purified the labeled product, trichloroacetic acid method for the determination of the radiochemical purity of the labeled product, in vitro cell binding assay to identify 13 1I sc 72 69 immuno-binding activity. Results ①13 1I labeling rate of 2 7.46%, the radioactivity of the labeled product was 1.0 2MBq / μg, the average radioactive chemical purity of 96.2 0%. The average radioactive concentration was 18.3 0 MBq / ml. ② In vitro binding analysis showed that the binding rate of 131I sc 72 69 to human bladder cancer T2 4 cells was 59.12%, while the binding rate to human umbilical vein endothelial cells was only 7.16% (P 0. 001). 13 1I sc 72 694 ℃ 7d after the binding rate with T2 4 cells is still 5 6.3 1%. Conclusions The 13 1I sc 72 69 prepared in this experiment has a radioactive chemical purity of> 95%, good immunocompetence and stability, and is suitable for radioactive imaging.